TNIK Therapeutics is developing small molecule inhibitors of TNIK, targeting cancer stem cells.
TNIK is the most downstream transcription regulator of the Wnt pathway. No Wnt signalling-inhibitors are currently approved for clinical use.
Targeting TNIK presents a fascinating therapeutic opportunity as it regulates the beta catenin-TCF4 transcription complex that is responsible for the activation of genes important for cancer stemness and proliferation.
The global CRC market is growing rapidly and is expected to exceed $10B by 2024
Keren Weiser, PhD – CSO
Dr. Weiser received her PhD in Biology from NYU and completed a postdoctoral fellowship at Weill Cornell. Keren previously held the position of director of scientific development at Immune Pharmaceuticals and worked on the development of bertilimumab, anti-eotaxin-1 antibody, and on nanomedicine.